Deutsche Bank Maintains Buy Rating on Akorn

By John Harris
Benzinga Staff Writer
December 15, 2011 10:23 AM

Symbols: AKRX, GENZ

Posted in: Analyst Color, Analyst Ratings

According to Deutsche Bank, Akorn (NASDAQ: AKRX) Buy rating is maintained.

Deutsche Bank said that ViroPharma received an SNDA approval for its oral antiinfective Vancocin (vancomycin, approx $300M 2011 sales) - which has been the target of generic filers since 2007 (Akorn was an early filer). “According to ViroPharma, Vancocin's updated label is predicated on new clinical safety and efficacy data on the treatment of circulating strains of C. difficile the company purchased from Sanofi (GENZ).”

Akorn closed yesterday at $10.70.

< Previous
Goldman Sachs Maintains Neutral Rating on Hewlett-Packard

Next >
Jefferies Maintains Buy Rating on Broadcom

Printer-friendly version

Send to friend

We're Loving

The Money Conversation Your Family Can't Delay Having

Insiders Are Selling These Two Radio Stocks

You Could Have Profited 14% on AOL by Using Benzinga Pro. Try It for Free Now!

The Most Dangerous States to Drive In

Cramer: Lehman Case 'Is a Travesty of Justice'

Benzinga's Premium Memberships

Options & Volatility Edge

Options & Volatility Edge is for those people who want to make money using cost effective options trading strategies. This product is for anyone—novices and experts. If you understand how to enter an options trade, you need Options & Volatility Edge.

Learn More >>
14 Day Free Trial!

Basic Premium
ETF Professor

The ETF Professor is truly an appropriate moniker, because the Professor spends hours everyday analyzing the charts of dozens of ETFs EVERY DAY.

Learn More >>
14 Day Free Trial!

Basic Premium
Winning Stocks

Winning Stocks tracks and analyzes attractive stocks that are poised to make great returns for the average investor. Investors receive the right information at the right time, which provides them with the possibility for great gains and the potential to beat the market.

Learn More >>
14 Day Free Trial!

Basic Premium

Real-Time Rumors

In this game, information is everything. You have to know what is happening before the Street begins trading against you utilizing the new information. We will provide you with that edge.

Learn More >>
14 Day Free Trial!

Basic Premium
Chart-Caster

From novice to pro, Chart-Caster delivers over $11,000 per month* in profitable trade setups across all time-frames from which members can evaluate, select, and replicate within their own trading accounts.

Learn More >>
14 Day Free Trial!

Basic Premium

Deutsche Bank Maintains Buy Rating on Akorn

Benzinga's Premium Memberships

More stories by John Harris

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social